Literature DB >> 22065769

Fcγ receptor IIB (FcγRIIB) maintains humoral tolerance in the human immune system in vivo.

Anne Baerenwaldt1, Anja Lux, Heike Danzer, Bernd M Spriewald, Evelyn Ullrich, Gordon Heidkamp, Diana Dudziak, Falk Nimmerjahn.   

Abstract

Maintenance of immunological tolerance is crucial to prevent development of autoimmune disease. The production of autoantibodies is a hallmark of many autoimmune diseases and studies in mouse model systems suggest that inhibitory signaling molecules may be important checkpoints of humoral tolerance. By generating humanized mice with normal and functionally impaired Fcγ receptor IIB (FcγRIIB) variants, we show that the inhibitory Fcγ-receptor is a checkpoint of humoral tolerance in the human immune system in vivo. Impaired human FcγRIIB function resulted in the generation of higher levels of serum immunoglobulins, the production of different autoantibody specificities, and a higher proportion of human plasmablasts and plasma cells in vivo. Our results suggest that the inhibitory FcγRIIB may be an important checkpoint of humoral tolerance in the human immune system.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22065769      PMCID: PMC3219118          DOI: 10.1073/pnas.1111810108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  FcgammaRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling.

Authors:  Hajime Kono; Chieko Kyogoku; Takeshi Suzuki; Naoyuki Tsuchiya; Hiroaki Honda; Kazuhiko Yamamoto; Katsushi Tokunaga; Zen-Ichiro Honda
Journal:  Hum Mol Genet       Date:  2005-08-22       Impact factor: 6.150

Review 2.  B cell selection and susceptibility to autoimmunity.

Authors:  Christine M Grimaldi; Ruthmarie Hicks; Betty Diamond
Journal:  J Immunol       Date:  2005-02-15       Impact factor: 5.422

3.  The inhibitory Fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells.

Authors:  Hidehiro Fukuyama; Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Nat Immunol       Date:  2004-12-12       Impact factor: 25.606

4.  Modulation of the immune response in pristane-induced lupus by expression of activation and inhibitory Fc receptors.

Authors:  Raphael Clynes; Nicola Calvani; Byron P Croker; Hanno B Richards
Journal:  Clin Exp Immunol       Date:  2005-08       Impact factor: 4.330

5.  Loss of function of a lupus-associated FcgammaRIIb polymorphism through exclusion from lipid rafts.

Authors:  R Andres Floto; Menna R Clatworthy; Karen R Heilbronn; Dalya R Rosner; Paul A MacAry; Angela Rankin; Paul J Lehner; Willem H Ouwehand; Janet M Allen; Nicholas A Watkins; Kenneth G C Smith
Journal:  Nat Med       Date:  2005-09-18       Impact factor: 53.440

6.  Restoration of tolerance in lupus by targeted inhibitory receptor expression.

Authors:  Tracy L McGaha; Brian Sorrentino; Jeffrey V Ravetch
Journal:  Science       Date:  2005-01-28       Impact factor: 47.728

7.  Decreased transcription of the human FCGR2B gene mediated by the -343 G/C promoter polymorphism and association with systemic lupus erythematosus.

Authors:  Marissa C Blank; Radu N Stefanescu; Emi Masuda; Francesc Marti; Philip D King; Patricia B Redecha; Robert J Wurzburger; Margaret G E Peterson; Shizuko Tanaka; Luminita Pricop
Journal:  Hum Genet       Date:  2005-05-14       Impact factor: 4.132

8.  A naturally occurring mutation in Fc gamma RIIA: a Q to K127 change confers unique IgG binding properties to the R131 allelic form of the receptor.

Authors:  C F Norris; L Pricop; S S Millard; S M Taylor; S Surrey; E Schwartz; J E Salmon; S E McKenzie
Journal:  Blood       Date:  1998-01-15       Impact factor: 22.113

9.  The Fc gammaRIIIA-158F allele is a risk factor for systemic lupus erythematosus.

Authors:  H R Koene; M Kleijer; A J Swaak; K E Sullivan; M Bijl; M A Petri; C G Kallenberg; D Roos; A E von dem Borne; M de Haas
Journal:  Arthritis Rheum       Date:  1998-10

10.  Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice.

Authors:  T Takai; M Ono; M Hikida; H Ohmori; J V Ravetch
Journal:  Nature       Date:  1996-01-25       Impact factor: 49.962

View more
  29 in total

Review 1.  IgG Fc Glycosylation in Human Immunity.

Authors:  Taia T Wang
Journal:  Curr Top Microbiol Immunol       Date:  2019       Impact factor: 4.291

2.  Defunctioning polymorphism in the immunoglobulin G inhibitory receptor (FcγRIIB-T/T232) does not impact on kidney transplant or recipient survival.

Authors:  Gerhard Opelz; Kenneth G C Smith; Menna R Clatworthy; Rebeccah J Matthews; Bernd Doehler; Lisa C Willcocks
Journal:  Transplantation       Date:  2014-08-15       Impact factor: 4.939

Review 3.  Intravenous immunoglobulin therapy: how does IgG modulate the immune system?

Authors:  Inessa Schwab; Falk Nimmerjahn
Journal:  Nat Rev Immunol       Date:  2013-02-15       Impact factor: 53.106

4.  Inhibitory Fcγ receptor is required for the maintenance of tolerance through distinct mechanisms.

Authors:  Fubin Li; Patrick Smith; Jeffrey V Ravetch
Journal:  J Immunol       Date:  2014-02-21       Impact factor: 5.422

Review 5.  Targeting B cells and autoantibodies in the therapy of autoimmune diseases.

Authors:  Daniela Kao; Anja Lux; Inessa Schwab; Falk Nimmerjahn
Journal:  Semin Immunopathol       Date:  2014-04-29       Impact factor: 9.623

6.  The Impact of FcγRI Binding on Immuno-PET.

Authors:  Delphine Vivier; Sai Kiran Sharma; Pierre Adumeau; Cindy Rodriguez; Kimberly Fung; Brian M Zeglis
Journal:  J Nucl Med       Date:  2019-02-07       Impact factor: 10.057

Review 7.  Translating Inhibitory Fc Receptor Biology into Novel Therapeutic Approaches.

Authors:  Falk Nimmerjahn
Journal:  J Clin Immunol       Date:  2016-03-08       Impact factor: 8.317

8.  FcγRIIb expression in early stage chronic lymphocytic leukemia.

Authors:  Rosa Bosch; Alba Mora; Eva Puy Vicente; Gerardo Ferrer; Sonia Jansà; Rajendra Damle; Sergey Gorlatov; Kanti Rai; Emili Montserrat; Josep Nomdedeu; Marta Pratcorona; Laura Blanco; Silvana Saavedra; Ana Garrido; Albert Esquirol; Irene Garcia; Miquel Granell; Rodrigo Martino; Julio Delgado; Jorge Sierra; Nicholas Chiorazzi; Carol Moreno
Journal:  Leuk Lymphoma       Date:  2017-04-04

9.  Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis.

Authors:  Prapaporn Pisitkun; Hye-Lin Ha; Hongshan Wang; Estefania Claudio; Caitlyn C Tivy; Hua Zhou; Tanya N Mayadas; Gabor G Illei; Ulrich Siebenlist
Journal:  Immunity       Date:  2012-11-01       Impact factor: 31.745

10.  Censoring of self-reactive B cells by follicular dendritic cell-displayed self-antigen.

Authors:  Irene W Yau; Matthew H Cato; Julia Jellusova; Tatiana Hurtado de Mendoza; Robert Brink; Robert C Rickert
Journal:  J Immunol       Date:  2013-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.